There is little that is certain and it's currently assumed that once ambient temperatures rise above 26C (80F), the virus will begin to dissipate. It's a bold assumption and not a given. What is safe(r) to assume though is that areas of high humidity provide the environment that allows the virus to fester..
If that is indeed so, it raises the question as to whether the virus can be transmitted via mosquito, as is the case with Dengue and the West Nile Virus
If so, obviously, added high risk in an ongoing pandemic.
I'm going to confine all my comments on this thread to the technical side. Here is the best paper we have on aerosol and surface stability of COVID-19:
https://www.medrxiv.org/content/10.1101/2020.03.09.20033217v1.full.pdf It is not clear whether warmer months will reduce the environmental stability of the virus though increased sunlight and UV radiation will help. It's highly doubtful that the virus can be transmitted by mosquitos as this is a mammalian and not an arbovirus. I'm reasonably confident that this is one thing you don't need to worry about.
I've been doing a lot of reading up on what the biopharma industry (my former employer) is doing to counter the pandemic. Perhaps the best ongoing discussion comes at Derek Lowe's website:
https://blogs.sciencemag.org/pipeline/ He's a drug discovery researcher in the pharma industry. I pretty much agree with him that there will not be a short term solution in terms of a drug to halt the pandemic. There are a few number of drugs in trials right now and Gilead's remdesivir, that was a putative Ebola drug, is in trials in the US and China (my understanding is this drug needs to be infused). Because it was examined during the Ebola outbreak a lot of testing has already been done. the big problem is it is a complicated drug to manufacture at scale. A second drug, camostat, is thought to work by preventing entry of the virus into cells; I think there may be a trial underway in China (this drug is approved in Japan so there may be good data regarding safety that could support quick approval). As Lowe states, that's about it. It's going to be a hard slog to screen lots of drugs and coming up with novel new approaches is a multi-year project.
One company represented at President Trump's round table two weeks ago, Regeneron, is working on a monoclonal antibody against COVID and stated they could make this at scale in a couple of months. This would be used in hospital settings for therapy. This is probably the best solution at hand and it's important to get this into the clinic ASAP.
The best approach is obviously a vaccine. There are several new approaches to quickly generating vaccine candidates based on RNA and DNA platforms. Unfortunately, these technologies have not been tested in humans. IMO, the one major failing of research agencies it was not funding preliminary trials of these platforms to look at safety and whether they were able to generate antibodies. This type of research could have been done in small trials to assess whether they really work as promised. We will start to see some early human trials in the next two months on several new vaccine candidates but this will not help resolve the current pandemic.